諾和諾德盤前跳漲 Ozempic 心血管保護功效優於禮來老藥
Novo Nordisk's stock price rose 6.01% in pre-market trading, marking the largest single-day increase in a month. The reason is that its diabetes drug Ozempic outperformed Eli Lilly's Trulicity in a survey of American patients, with Ozempic patients having a 23% lower risk of heart attack, stroke, or death. The study involved nearly 60,000 diabetes and heart disease patients, and Novo Nordisk announced the results at the European Association for the Study of Diabetes conference
According to the Zhitong Finance APP, Novo Nordisk (NVO.US) saw its stock price record the largest single-day increase in a month, due to its diabetes blockbuster drug Ozempic outperforming Eli Lilly's (LLY.US) older drug Trulicity in a real-world study involving certain patients in the United States.
Novo Nordisk reported at the European Association for the Study of Diabetes (EAD) conference in Vienna that Medicare patients taking Ozempic had a 23% lower risk of heart attack, stroke, or death compared to those taking Trulicity. The study tracked nearly 60,000 patients with diabetes and heart disease.
Both Ozempic and Trulicity belong to the GLP-1 class of drugs, which have revolutionized weight loss treatment. The idea that "certain drugs are more effective than others in preventing heart disease" is the cornerstone of Novo Nordisk's competition with Eli Lilly in the fiercely competitive field of obesity and related diseases. Eli Lilly continues to capture market share with its new drugs Mounjaro and Zepbound.
Novo Nordisk's stock price rose by 6.5% in Copenhagen at one point.
Another head-to-head study was also presented at Thursday's meeting, showing that Mounjaro had a similar effect to Trulicity in reducing the risk of heart attack, stroke, and death. However, these two studies are not comparable, as one was a randomized trial while the other was a real-world outcomes survey.
As of the time of writing on Thursday before the U.S. stock market opened, Novo Nordisk was up 6.01%, trading at $61.70
